Enables neuregulin receptor activity. Involved in ERBB2-ERBB3 signaling pathway; Schwann cell development; and myelination. Acts upstream of or within several processes, including negative regulation of motor neuron apoptotic process; nervous system development; and positive regulation of calcineurin-NFAT signaling cascade. Located in apical plasma membrane and lateral plasma membrane. Is active in plasma membrane. Is expressed in several structures, including alimentary system; genitourinary system; heart; nervous system; and sensory organ epithelium. Human ortholog(s) of this gene implicated in lethal congenital contracture syndrome 2; lung adenocarcinoma; lung non-small cell carcinoma; and neuronal intestinal dysplasia type A. Orthologous to human ERBB3 (erb-b2 receptor tyrosine kinase 3).
[Estradiol co-treated with TGFB1 protein] results in decreased expression of ERBB3 mRNA, EGF protein promotes the reaction [Estradiol results in decreased expression of ERBB3 mRNA]
Fluorouracil promotes the reaction [Curcumin results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB3 protein], Fluorouracil results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB3 protein
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of ERBB3 protein
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB3 mRNA
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [beta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]] more ...
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB3 mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB3 mRNA, [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB3 mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB3 mRNA, [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB3 mRNA
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERBB3 mRNA
Curcumin promotes the reaction [Folfox protocol results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB3 protein] more ...
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of ERBB3 protein
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of ERBB3 protein
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB3 mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB3 mRNA
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERBB3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB3 mRNA, [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB3 mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB3 mRNA
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in increased expression of ERBB3 protein
Fulvestrant inhibits the reaction [4, 4'-hexafluorisopropylidene diphenol results in increased expression of and results in increased phosphorylation of ERBB3 protein]
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERBB3 mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB3 mRNA
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [beta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfide results in decreased expression of ERBB3 protein], benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfone results in decreased expression of ERBB3 protein]
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA
PANX1 gene mutant form promotes the reaction [Acetaminophen results in decreased expression of ERBB3 mRNA], YAP1 gene mutant form promotes the reaction [Acetaminophen results in increased expression of ERBB3 mRNA]
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB3 mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB3 mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB3 mRNA
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERBB3 mRNA
tephrosin inhibits the reaction [NRG1 protein affects the phosphorylation of ERBB3 protein], tephrosin results in increased degradation of and results in decreased phosphorylation of ERBB3 protein
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB3 mRNA
[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA
Immunohistochemical expression patterns of the HER4 receptors in normal mucosa and in laryngeal squamous cell carcinomas: antioncogenic significance of the HER4 protein in laryngeal squamous cell carcinoma.
Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients.
Expression of neuregulin and ErbB3 and ErbB4 after a traumatic lesion in the ventral funiculus of the spinal cord and in the intact primary olfactory system.
Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer.